Caribou Biosciences, Inc.

1.76 USD
+0.04 (+2.33%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Caribou Biosciences, Inc. stock is down -43.41% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 June’s closed higher than May. 100% of analysts rate it a buy.

About Caribou Biosciences, Inc.

Caribou Biosciences, Inc. engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010 and CB-011, which are in phase 1 clinical trials to treat relapsed or refractory B cell non-Hodgkin lymphoma.